Contents

VISUAL I: Adalimumab in Patients with Active Noninfectious Uveitis


Main finding: Adalimumab significantly decreased the rate of treatment failure and loss of visual acuity in patients with active, non-infectious intermediate, posterior, or panuveitic uveitis despite being on systemic corticosteroids for 2 or more weeks.

 

Study characteristics:

 

  • Name: VISUAL I study
  • Purpose: To assess the efficacy and safety of adalimumab as a glucocorticoid-sparing agent for the treatment of active noninfectious uveitis
  • Type: Randomised controlled Trial
  • Condition: Non-infectious intermediate, posterior, and panuveitic uveitis controlled by corticosteroids.
  • Year results published: 2016

Participants: ≥18 years, active non-infectious intermediate, posterior or panuveitic uveitis, despite being on prednisone (10-60mg/day) or an equivalent glucocorticoid for ≥2 weeks

 

  • n=217

 

Intervention:

 

Group 1: Adalimumab (80mg loading dose then 40mg every 2 weeks)
Group 2: Placebo

Both groups received prednisone burst followed by tapering of prednisone over 15 weeks.

 

The median time to treatment failure was 24 weeks in the adalimumab group vs 13 weeks in the placebo group.

 

Subjects receiving adalimumab were less likely than placebo to have treatment failure (hazard ratio 0.50).

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed